Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) EBITDA Margin (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed EBITDA Margin for 11 consecutive years, with 178.23% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 37503.0% to 178.23% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 295.16% through Dec 2025, down 21348.0% year-over-year, with the annual reading at 295.44% for FY2025, 21374.0% down from the prior year.
  • EBITDA Margin hit 178.23% in Q4 2025 for Voyager Therapeutics, up from 206.99% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1516.65% in Q4 2022 to a low of 3252.89% in Q1 2022.
  • Historically, EBITDA Margin has averaged 584.34% across 5 years, with a median of 269.91% in 2021.
  • Biggest five-year swings in EBITDA Margin: plummeted -292005bps in 2022 and later surged 333538bps in 2023.
  • Year by year, EBITDA Margin stood at 20.3% in 2021, then surged by 7371bps to 1516.65% in 2022, then tumbled by -96bps to 62.81% in 2023, then crashed by -981bps to 553.26% in 2024, then surged by 68bps to 178.23% in 2025.
  • Business Quant data shows EBITDA Margin for VYGR at 178.23% in Q4 2025, 206.99% in Q3 2025, and 642.38% in Q2 2025.